Thyroid Cancer Newswire

Thyroid Cancer Newswire

Comprehensive Real-Time News Feed for Thyroid Cancer.

Results 1 - 20 of 676 in Thyroid Cancer

  1. Cancer Stocks: 2 to Buy, 1 to AvoidRead the original story w/Photo

    5 hrs ago | The Motley Fool

    ... Cabometyx & Cometriq), can produce clinically meaningful anti-tumor responses in patients with medullary thyroid cancer and advanced renal cancer, helping the company to garner FDA-approvals for both indications. The biotech is now hoping to add ...

    Comment?

  2. Drug targeting BRAF mutation slows thyroid cancer, tooRead the original story w/Photo

    17 hrs ago | PhysOrg Weblog

    In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients. In the latest example, researchers from Penn Medicine and other institutions found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib-originally approved for melanoma patients with the mutation-showed promising anti-tumor activity in a third of patients.

    Comment?

  3. Personalized Medicine Meets Thyroid Cancer: Drug Targeting BRAF Mutation Helps PatientsRead the original story

    Friday | Newswise

    In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients. In the latest example, researchers from Penn Medicine and other institutions found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib - originally approved for melanoma patients with the mutation - showed promising anti-tumor activity in a third of patients.

    Comment?

  4. Scans Not Worthwhile for Most Thyroid CancersRead the original story w/Photo

    Thursday Jul 21 | WebMD

    ... that interest you. THURSDAY, July 21, 2016 (HealthDay News) -- Having scans after treatment does not improve thyroid cancer patients' chances of survival, a new study shows. Researchers from the University of Michigan looked at more than 28,000 ...

    Comment?

  5. Increased screenings after thyroid cancer associated with increased treatment for its recurrenceRead the original story w/Photo

    Friday | WSJV-TV South Bend

    Increased screenings after a thyroid cancer diagnosis are associated with increased treatment for its recurrence but no clear improvement in surviving the disease. Over the past two decades thyroid cancer cases have risen.

    Comment?

  6. Exelixis Inc. (EXEL) Hits New 12-Month High at $8.55Read the original story w/Photo

    Friday | Daily Political

    ... n various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.

    Comment?

  7. Letter: Charity party successRead the original story w/Photo

    Friday | Penarth Times

    ... the Deli, High Street Barry - raising just under A 1,300, which will make a vast difference to the work that Thyroid Cancer Support Group Wales can do to help those who are affected by this very rare form of cancer. As a group we value the support ...

    Comment?

  8. Scans Not Worthwhile for Most Thyroid Cancers: StudyRead the original story w/Photo

    Thursday Jul 21 | MedicineNet

    Researchers from the University of Michigan looked at more than 28,000 patients in the United States who were diagnosed with thyroid cancer between 1998 and 2011. After treatment, 57 percent of the patients had at least one ultrasound , 24 percent had a radioiodine scan and 15 percent had a PET scan to monitor for signs of the return of their cancer.

    Comment?

  9. Leerink Swann Reiterates Buy Rating for Exelixis Inc.Read the original story w/Photo

    Thursday Jul 21 | Daily Political

    ... various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to ...

    Comment?

  10. Thyroid issues: Goiters and other conditions pinpoint the thyroid gland's effect on the bodyRead the original story w/Photo

    Thursday Jul 21 | RDH

    ... growth or enlargement in the thyroid area should alert the health-care provider to the possibility of thyroid cancer until proven otherwise. Sometimes larger masses of tissue may be observed in the neck, and these can become quite large, ...

    Comment?

  11. Five-year survival rate for cancer patients improving, report showsRead the original story w/Photo

    Thursday Jul 21 | The Japan Times

    ... on to live for at least five more years, followed by 92.2 percent of skin cancer patients and 89.5 percent of thyroid cancer patients. At the other end of the spectrum were men with lung cancer, gallbladder/bile duct cancer and pancreatic cancer, ...

    Comment?

  12. Study raises concerns over unnecessary imaging after thyroid cancerRead the original story w/Photo

    Thursday Jul 21 | Medical News Today

    A marked rise in use of imaging tests after thyroid cancer has been associated with increased treatment for recurrence, but no clear improvement in survival from the disease, finds a study in The BMJ . These findings highlight the importance of curbing unnecessary imaging and tailoring imaging after treatment to patient risk, say the researchers.

    Comment?

  13. Imaging after thyroid cancer treatment does not necessarily mean better outcomesRead the original story w/Photo

    Wednesday Jul 20 | PhysOrg Weblog

    Researchers from the University of Michigan Comprehensive Cancer Center looked at 28,220 patients diagnosed with differentiated thyroid cancer, using data from the Surveillance Epidemiology and End Results-Medicare linked database. They used claims data to track ultrasound, PET scans and radioiodine scans in patients diagnosed with thyroid cancer between 1998 to 2011.

    Comment?

  14. Analysts Anticipate Exelixis Inc. (NASDAQ:EXEL) to Post -$0.27 Earnings Per ShareRead the original story w/Photo

    Tuesday Jul 19 | AmericanBankingNews.com

    ... various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to ...

    Comment?

  15. 'My life had been shook' - How yoga helped Sile Seoige rebuild her mind and body after cancerRead the original story w/Photo

    Tuesday Jul 19 | Independent.ie

    ... on for yourself." SA le attended a number of yoga classes over the years, but it wasn't until her battle with thyroid cancer in 2012, that the practice took on a whole new dimension for her. "I would have done the odd yoga class down through the ...

    Comment?

  16. Heroin's human toll: Workplace injury left man Lorain man addicted to painkillers, heroinRead the original story w/Photo

    Monday Jul 18 | Cleveland.com

    ... and caused four bulging discs in his lower back. The situation worsened when doctors discovered he had thyroid cancer and a cyst at the bottom of his brain stem. He stayed in the hospital several days and took medication to ease the pain. But the ...

    Comment?

  17. Lombardi Walk/Run to Tackle Cancer joins Festa ItalianaRead the original story w/Photo

    Monday Jul 18 | Milwaukee Journal-Sentinal

    ... family. Vella's mother, Maria Vella, battled lymphoma years ago. His sister-in-law, Ann Vella, also battled thyroid cancer. They're both in remission now, and the relief can be seen in Vella's face. The Italian Community Center is partnering with ...

    Comment?

  18. Exelixis Inc. (EXEL) Stock Price Up 2.2%Read the original story w/Photo

    Sunday Jul 17 | Daily Political

    ... various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to ...

    Comment?

  19. Exelixis Inc. (EXEL) Trading Up 2.2%Read the original story w/Photo

    Friday Jul 15 | Daily Political

    ... n various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.

    Comment?

  20. Dr. Nghi Nguyen Recognized by Marquis Who's Who for Excellence in Nuclear MedicineRead the original story w/Photo

    Thursday Jul 14 | 24-7 Press Release

    ... areas of competency and specialty include radioiodine treatment of benign thyroid diseases and differentiated thyroid cancer, SPECT/CT, PET/CT, and PET/MRI as part of clinical nuclear medicine and molecular imaging. His clinical and research ...

    Comment?